Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

被引：6

作者：

Gori, Niccolo ^{[1
,2
]}

Sernicola, Alvise ^{[3
]}

Tolino, Ersilia ^{[4
]}

Mariano, Maria ^{[5
]}

Galluzzo, Marco ^{[6
,7
]}

Moretta, Gaia ^{[8
]}

Coppola, Rosa ^{[9
,10
]}

D'Alessio, Andrea ^{[11
]}

Sansone, Massimo ^{[12
]}

Maffei, Virginia ^{[6
,7
]}

Paolino, Claudia ^{[8
]}

Ferrao, Cristian ^{[13
]}

Cascia, Lauro ^{[14
]}

Addio, Paola ^{[15
]}

Di Nardo, Lucia ^{[1
]}

Chiricozzi, Andrea ^{[1
,2
]}

Del Duca, Ester ^{[3
]}

Cristaudo, Antonio ^{[5
]}

Bianchi, Luca ^{[6
,7
]}

Pallotta, Sabatino ^{[8
]}

Panasiti, Vincenzo ^{[9
,10
]}

Pellacani, Giovanni ^{[3
]}

Potenza, Concetta ^{[4
]}

Peris, Ketty ^{[1
,2
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dipartimento Med & Chirurg Traslaz, Dermatol, Rome, Italy

[2] Fdn Policlin Univ A Gemelli, Dipartimento Sci Med & Chirurg, Dermatol, IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy

[3] Sapienza Univ Rome, Dept Clin Internal Anesthesiol & Cardiovasc Sci, Dermatol Clin, Rome, Italy

[4] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Polo Pontino, Italy

[5] San Gallicano Dermatol Inst IRCCS, Dept Dermatol, Rome, Italy

[6] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy

[7] Fdn Policlin Tor Vergata, Dermatol Unit, Rome, Italy

[8] Dermatol Res Hosp, Dermatol Unit, IDI IRCCS, Rome, Italy

[9] Univ Campus Biomed, Fdn Policlin, Dermatol, Rome, Italy

[10] Univ Campus Biomed Roma, Dept Med & Surg, Res Unit Dermatol, Rome, Italy

[11] Univ A Gemelli, UOC Farm Fdn Policlin, IRCCS, Rome, Italy

[12] Hosp Pharm, IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[13] Univ Campus Biomed, UOC Farm Osped Fdn Policlin, Rome, Italy

[14] UOC Farm Ospedaliera, Azienda Osped Univ Policlin Umberto 1, Viale Policlin 155, Rome, Italy

[15] UOC Assistenza farmaceut, Policlin Osped Fiorini, Terracina Asl Latina, Rome, Italy

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2023年 / 34卷 / 01期

关键词：

Atopic dermatitis; dupilumab; drug survival; INADEQUATE RESPONSE; MANAGEMENT; PLACEBO;

D O I：

10.1080/09546634.2023.2230685

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Objectives The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients' treatment persistence. Material and methods This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021. Results A total of 659 adult patients (345 male [52.3%], mean age: 42.8 years) with an average treatment duration of 23.3 months were enrolled in the study. Overall, 88.6% and 76.1% of patients were still on treatment after 12 and 24 months, respectively. The drug survival rate for discontinuation due to AEs and dupilumab ineffectiveness was 95.0% at 12 months and 90.0% at 24 months. The main reasons for drug discontinuation included inefficacy (29.6%), failed compliance (17.4%), persistent efficacy (20.4%) and adverse events (7.8%). Adult AD onset (& GE;18 years) and EASI score severity measured at the last follow-up visit were the only factors significantly associated with lower drug survival. Conclusion This study revealed an increased cumulative probability of dupilumab survival at 2 years, reflected by a sustained effectiveness and a favorable safety profile of the drug.

引用

页数：7

共 25 条

[1] No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
Blauvelt, Andrew
Wollenberg, Andreas
Eichenfield, Lawrence F.
Zhang, Haixin
Sierka, Debra
Khokhar, Faisal A.
Vakil, Jignesh
Shabbir, Arsalan
Marco, Ainara Rodriguez
Cyr, Sonya L.
[J]. ADVANCES IN THERAPY, 2023, 40 (01) : 367 - 380
[2] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Blauvelt, Andrew
de Bruin-Weller, Marjolein
Gooderham, Melinda
Cather, Jennifer C.
Weisman, Jamie
Pariser, David
Simpson, Eric L.
Papp, Kim A.
Hong, H. Chih-Ho
Rubel, Diana
Foley, Peter
Prens, Errol
Griffiths, Christopher E. M.
Etoh, Takafumi
Pinto, Pedro Herranz
Pujol, Ramon M.
Szepietowski, Jacek C.
Ettler, Karel
Kemeny, Lajos
Zhu, Xiaoping
Akinlade, Bolanle
Hultsch, Thomas
Mastey, Vera
Gadkari, Abhijit
Eckert, Laurent
Amin, Nikhil
Graham, Neil M. H.
Pirozzi, Gianluca
Stahl, Neil
Yancopoulos, George D.
Shumel, Brad
[J]. LANCET, 2017, 389 (10086) : 2287 - 2303
[3] Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients
Dal Bello, Giacomo
Maurelli, Martina
Schena, Donatella
Girolomoni, Giampiero
Gisondi, Paolo
[J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
[4] Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
de Bruin-Weller, M.
Thaci, D.
Smith, C. H.
Reich, K.
Cork, M. J.
Radin, A.
Zhang, Q.
Akinlade, B.
Gadkari, A.
Eckert, L.
Hultsch, T.
Chen, Z.
Pirozzi, G.
Graham, N. M. H.
Shumel, B.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1083 - 1101
[5] A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
Fargnoli, M. C.
Esposito, M.
Ferrucci, S.
Girolomoni, G.
Offidani, A.
Patrizi, A.
Peris, K.
Costanzo, A.
Malara, G.
Pellacani, G.
Romanelli, M.
Amerio, P.
Cristaudo, A.
Flori, M. L.
Motolese, A.
Betto, P.
Patruno, C.
Pigatto, P.
Peccianti, C.
Stinco, G.
Zalaudek, I.
Bianchi, L.
Boccaletti, V.
Cannavo, S. P.
Cusano, F.
Lembo, S.
Mozzillo, R.
Gallo, R.
Potenza, C.
Rongioletti, F.
Tiberio, R.
Grieco, T.
Micali, G.
Persechino, S.
Pettinato, M.
Pucci, S.
Stingeni, L.
Caruso, C.
Argenziano, G.
[J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 1146 - 1149
[6] Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
Georgakopoulos, Jorge R.
Felfeli, Tina
Drucker, Aaron M.
Jo, Christine E.
Piguet, Vincent
Yeung, Jensen
[J]. JAAD INTERNATIONAL, 2021, 4 : 67 - 69
[7] Response to the article by Narla et al "Management of inadequate response and adverse effects to dupilumab in atopic dermatitis"
Gori, Niccolo
Chiricozzi, Andrea
Peris, Ketty
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : E65 - E66
[8] National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis
Gori, Niccolo
Chiricozzi, Andrea
Marsili, Franco
Ferrucci, Silvia Mariel
Amerio, Paolo
Battarra, Vincenzo
Campitiello, Salvatore
Castelli, Antonio
Congedo, Maurizio
Corazza, Monica
Cristaudo, Antonio
Fabbrocini, Gabriella
Girolomoni, Giampiero
Malara, Giovanna
Micali, Giuseppe
Palazzo, Giovanni
Parodi, Aurora
Patrizi, Annalisa
Pellacani, Giovanni
Pigatto, Paolo
Provenzano, Eugenio
Quaglino, Pietro
Romanelli, Marco
Rossi, Mariateresa
Savoia, Paola
Peris, Ketty
[J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
[9] Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy
Gori, Niccolo
Chiricozzi, Andrea
Malvaso, Dalma
D'Urso, Dario Francesco
Caldarola, Giacomo
De Simone, Clara
Peris, Ketty
[J]. DERMATOLOGY, 2021, 237 (04) : 535 - 541
[10] Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States
Khosravi, Hasan
Zhang, Sophia
Anderson, Alyce M.
Ferris, Laura K.
Choudhary, Sonal
Patton, Timothy
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 1023 - 1024

← 1 2 3 →